Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
SUCCESSFUL PASSING OF EU QP AUDIT ON TOT BIOPHARM'S COMMERCIAL PRODUCTION BASE FOR MONOCLONAL ANTIBODY DRUG SUBSTANCES AND ANTIBODY DRUG CONJUGATES 2022-10-27 08:00
Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares 2022-06-02 08:00
TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China 2021-12-02 08:00
TOT BIOPHARM Anounces 2021 Interim Results 2021-08-13 10:59
TOT BIOPHARM (1875.HK) Proceeded with IPO raising over HK$500 million 2019-11-07 19:04
1